These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7888204)

  • 21. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
    Neurath AR; Strick N; Debnath AK
    J Mol Recognit; 1995; 8(6):345-57. PubMed ID: 9052975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B.
    Moulard M; Mabrouk K; Martin I; Van Rietschoten J; Rochat H; Sabatier JM
    J Pept Res; 1999 Jun; 53(6):647-55. PubMed ID: 10408339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity of inhibition of HIV-1 integrase and virus replication by G-quartet oligonucleotides.
    Jing N; Marchand C; Guan Y; Liu J; Pallansch L; Lackman-Smith C; De Clercq E; Pommier Y
    DNA Cell Biol; 2001 Aug; 20(8):499-508. PubMed ID: 11560782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of a hydrophobic tripeptide on human immunodeficiency virus type 1 (HIV-1)-induced syncytium formation and viral infectivity.
    Konopka K; Pretzer E; Düzgünes N
    Biochem Biophys Res Commun; 1995 Mar; 208(1):75-81. PubMed ID: 7887968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1.
    Ojwang JO; Buckheit RW; Pommier Y; Mazumder A; De Vreese K; Esté JA; Reymen D; Pallansch LA; Lackman-Smith C; Wallace TL
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2426-35. PubMed ID: 8585721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralization of HIV-1 and inhibition of HIV-1-induced syncytia by 1,8-naphthalimide photoactive compound.
    Chanh TC; Lewis DE; Allan JS; Sogandares-Bernal F; Judy MM; Utecht RE; Matthews JL
    AIDS Res Hum Retroviruses; 1993 Sep; 9(9):891-6. PubMed ID: 8257636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs.
    Azad RF; Brown-Driver V; Buckheit RW; Anderson KP
    Antiviral Res; 1995 Oct; 28(2):101-11. PubMed ID: 8585764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inactivation of HIV infectivity by the chlorite-oxygen reaction product tetrachlorodecaoxygen.
    Ennen J; Werner K; Kühne FW; Kurth R
    AIDS; 1993 Sep; 7(9):1205-12. PubMed ID: 8216977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
    Delézay O; Hammache D; Fantini J; Yahi N
    Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Chong H; Zhu Y; Yu D; He Y
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Properties of quadruplex oligonucleotides with anti-HIV-1 activity.
    Tamura Y; Yoshida M; Suzuki J; Hiratou T; Miyano-Kurosaki N; Takai K; Takaku H
    Nucleic Acids Symp Ser; 2000; (44):181-2. PubMed ID: 12903328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents.
    Yamamoto N; Schols D; De Clercq E; Debyser Z; Pauwels R; Balzarini J; Nakashima H; Baba M; Hosoya M; Snoeck R
    Mol Pharmacol; 1992 Dec; 42(6):1109-17. PubMed ID: 1282664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of action of N-butyl deoxynojirimycin in inhibiting HIV-1 infection and activity in combination with nucleoside analogs.
    Ratner L; Vander Heyden N
    AIDS Res Hum Retroviruses; 1993 Apr; 9(4):291-7. PubMed ID: 8390276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Azasugar-containing phosphorothioate oligonucleotide (AZPSON) DBM-2198 inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking HIV-1 gp120 without affecting the V3 region.
    Lee J; Byeon SE; Jung JY; Kang MH; Park YJ; Jung KE; Bae YS
    Mol Cells; 2015; 38(2):122-9. PubMed ID: 25623024
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guanine-rich oligonucleotide modified at the 5' terminal by dimethoxytrityl residue inhibits HIV-1 replication by specific interaction with the envelope glycoprotein.
    Agatsuma T; Yamamoto I; Furukawa H; Nishigaki T
    Antiviral Res; 1996 Jul; 31(3):137-48. PubMed ID: 8811198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. V3-mediated heparin neutralization of HIV type 1.
    Javaherian K; Khiroya R; Quinlan C; Boyd JG; Hanham KA
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1421-3. PubMed ID: 7888195
    [No Abstract]   [Full Text] [Related]  

  • 38. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.
    De Clercq E; Yamamoto N; Pauwels R; Baba M; Schols D; Nakashima H; Balzarini J; Debyser Z; Murrer BA; Schwartz D
    Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5286-90. PubMed ID: 1608936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents.
    Buckheit RW; Germany-Decker J; Hollingshead MG; Allen LB; Shannon WM; Janssen PA; Chirigos MA
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1097-106. PubMed ID: 7508723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1.
    Debnath AK; Jiang S; Strick N; Lin K; Haberfield P; Neurath AR
    J Med Chem; 1994 Apr; 37(8):1099-108. PubMed ID: 8164251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.